![Stephen R. Donahue](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen R. Donahue
Geen lopende functies
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Oren M. Becker | M | - |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Mark Gabrielson | M | 68 | 3 jaar | |
James Fordyce | M | 81 | 1 jaar | |
Ben Palleiko | M | 58 | 1 jaar | |
Fredrick Frank | M | 92 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | 5 jaar |
David L. Urdal | M | 74 | 3 jaar | |
Ian Smith | M | 58 |
Predix Pharmaceuticals, Inc.
![]() Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | 1 jaar |
Julian Adams | M | 69 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Michael Kauffman | M | 60 |
Predix Pharmaceuticals, Inc.
![]() Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | 4 jaar |
Kimberlee Drapkin | F | 56 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | 1 jaar |
David Collier | M | 61 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Christine H. Wang | F | - |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Yigal Erlich | M | 84 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 13 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Stephen R. Donahue
- Persoonlijk netwerk